P
Pfenex
Pfenex develops biosimilar therapeutics and novel vaccines for the treatment and prevention of critical human health issues
About Pfenex
Pfenex Inc. is a biotechnology company specializing in the development of protein therapeutics aimed at transforming patient outcomes. Operating in the pharmaceutical and healthcare market, Pfenex focuses on creating and commercializing biosimilar and novel biologic drugs. The company serves a diverse range of clients, including healthcare providers, pharmaceutical companies, and patients in need of advanced therapeutic options. Pfenex's business model revolves around leveraging its proprietary protein expression technology to develop high-quality, cost-effective therapeutic proteins. The company generates revenue through the sale of its FDA-approved products, such as PF708 for osteoporosis, and through partnerships and licensing agreements for its pipeline candidates. Pfenex's commitment to innovation and patient care positions it as a key player in the biopharmaceutical industry.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2009
- Headquarters
- San Diego, United States
- Listing
- IPO 2014
- Sector
- Biotech & Life Sciences
- Power Law
- Colt$25–100M revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Signet Healthcare Partners
Dow
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Pfenex on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Pfenex on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.